AstraZeneca (AZN), Thursday announced a collaboration with Turbine, a biotechnology company specializing in AI-powered virtual biological experiments, to advance the discovery of antibody-drug conjugates.
In order to minimize the need for intensive laboratory screening, optimize ADC positioning, and predict response mechanisms, the partnership will make use of Turbine's simulation platform.
By merging AstraZeneca's experimental data with Turbine's virtual models, the partnership seeks to increase the speed and effectiveness of ADC discovery.
The platform's lab-in-the-loop methodology will analyze results from thousands of in silico models, minimizing experimental burden and providing mechanistic insights to inform future clinical approaches.
This is an extension of the companies' previous collaboration to investigate therapy resistance and biomarker discovery using Turbine's Simulated CellTM technology.
AZN is currently trading at $86.23, up $0.85 or 1.00 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.